NCT00865267View on ClinicalTrials.gov

The Dose-response Study of Topically Delivered Halobetasol Propionate Ointment in Normal Skin in Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

December 31, 2003

Primary Completion Date

December 31, 2003

Study Completion Date

December 31, 2003

Conditions
Healthy
Interventions
DRUG

Ultravate® 0.05% ointment, single exposure

A: Experimental Subjects received Bristol-Myers Squibb Company formulated products

Trial Locations (1)

92128

DermTech International, San Diego

Sponsors

Lead Sponsor

Actavis Inc.
All Listed Sponsors
lead

Actavis Inc.

INDUSTRY

NCT00865267 - The Dose-response Study of Topically Delivered Halobetasol Propionate Ointment in Normal Skin in Healthy Adult Subjects | Biotech Hunter | Biotech Hunter